Breakthrough in Cancer Therapy: Researchers Develop Innovative Nanoplatform for Synergistic Treatment

Strategic Insights -

Research conducted at Dalian Medical University in Dalian, People's Republic of China, has led to the development of a novel cascade-responsive nanoplatform for synergistic cancer therapy. This platform, tailor-made to address the complex characteristics of the tumor microenvironment (TME), integrates photodynamic therapy (PDT), chemotherapy, and immunotherapy to achieve multifaceted synergy. The researchers utilized functional nanoparticles that, upon near-infrared (NIR) light activation, initiate PDT to produce reactive oxygen species (ROS), exacerbating TME hypoxia and facilitating the release of immunomodulators and chemotherapeutic agents.

Key Takeaways:

  • The novel nanoplatform integrates PDT, chemotherapy, and immunotherapy to achieve multifaceted synergy, addressing the complex characteristics of the TME.
  • The platform comprises two functional nanoparticles: IR808/Resiquimod prodrug nanoparticles (IR808/R848-PRO NPs) and Doxorubicin prodrug nanoparticles (DOX-PRO NPs), designed to release immunomodulators and chemotherapeutic agents in response to NIR light and hypoxia.
  • The in vitro and in vivo experiments demonstrated that this platform enhances T-cell responses, promotes dendritic cell maturation, polarizes tumor-associated macrophages (TAMs), and significantly suppresses tumor growth with good biocompatibility.
  • The researchers report that this synergistic approach leads to a cascade of reactions, amplifying the immune activation triggered by R848, and resulting in a significant suppression of tumor growth.
  • The study proposes an innovative multifunctional nanoplatform that offers a novel strategy for treating tumors with hypoxia and immune suppression characteristics.
  • The research has been peer-reviewed and published in the Chemical Engineering Journal (Elsevier).

Statistics:

  • 516 is the volume number of the scientific journal Chemical Engineering Journal in which this research was published.
  • 22 researchers from Dalian Medical University contributed to this study, including Lixue Chen, Chunyun Xu, Yanfang Ding, Jingjing Qi, Peng Chu, Hongjie Huo, Zhuang Wang, Qingxuan Han, Yuan Liang, Ning Yang, Youwei Xu, Lei Li, and Ligeng Xu.

Sources:

  • NewsRx. Data on Cancer Detailed by Researchers at Dalian Medical University (Cascade-responsive Nanoplatform for Synergistic Cancer Therapy Via Ros Amplification and Hypoxia Targeting). Immunotherapy Weekly. July 23, 2025; p 609.
  • Cascade-responsive Nanoplatform for Synergistic Cancer Therapy Via Ros Amplification and Hypoxia Targeting. Chemical Engineering Journal, 2025;516.
  • Elsevier Science Sa, PO Box 564, 1001 Lausanne, Switzerland (publisher of Chemical Engineering Journal).
  • Dalian Medical University, College of Pharmacy, College of Basic Medical Sciences, Dalian 116044, People's Republic of China (research institution).